Inventor · disambiguated record
Jian Luo
Also filed as: LUO JIAN · LUO JIAN YUAN
38 granted patents·16 pending applications·744 citations·filing 1995–2023
98Inventor score
Files withNGM BIOPHARMACEUTICALS INC21METABOLEX INC7SHAMAN PHARMACEUTICALS INC6UNIV LELAND STANFORD JUNIOR6AMGEN INC3
Top patents by PatentIndex Score
54 records- 0197US9974833B2Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having pregnancy intrahepatic cholestasisNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted May 22, 2018·19 cites·54 claims
- 0297US9895416B2Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having cholestasisNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Feb 20, 2018·25 cites·54 claims
- 0397US9889177B2Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having primary sclerosing cholangitisNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Feb 13, 2018·25 cites·54 claims
- 0497US9889178B2Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having nonalcoholic steatohepatitisNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Feb 13, 2018·25 cites·54 claims
- 0597US9878008B2Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having bile acid diarrhea or bile acid malabsorptionNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Jan 30, 2018·26 cites·54 claims
- 0697US9878009B2Methods of using compositions comprising variants and fusions of FGF19 polypeptides for modulating bile acid homeostasis in a subject having error of bile acid synthesisNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Jan 30, 2018·25 cites·54 claims
- 0797US9273107B2Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseasesNGM BIOPHARMACEUTICALS INC·Filed 2013·Granted Mar 1, 2016·36 cites·63 claims
- 0895US10434144B2Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disordersNGM BIOPHARMACEUTICALS INC·Filed 2015·Granted Oct 8, 2019·11 cites·9 claims
- 0995US6613802B1Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemiaMETABOLEX INC·Filed 2000·Granted Sep 2, 2003·98 cites·6 claims
- 1094US9925242B2Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitisNGM BIOPHARMACEUTICALS INC·Filed 2013·Granted Mar 27, 2018·25 cites·52 claims
- 1194US9770486B2Methods of neuroprotection involving macrophage colony stimulating factor receptor agonistsUNIV LELAND STANFORD JUNIOR·Filed 2015·Granted Sep 26, 2017·17 cites·15 claims
- 1291US6646004B1Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemiaMETABOLEX INC·Filed 2000·Granted Nov 11, 2003·40 cites·17 claims
- 1391US5827898AUse of bisphenolic compounds to treat type II diabetesSHAMAN PHARMACEUTICALS INC·Filed 1996·Granted Oct 27, 1998·123 cites·3 claims
- 1489US10744185B2Methods of using variants of FGF19 polypeptides for the treatment of pruritusNGM BIOPHARMACEUTICALS INC·Filed 2016·Granted Aug 18, 2020·7 cites·52 claims
- 1589US7816367B2Compounds, pharmaceutical compositions and methods for use in treating metabolic disordersAMGEN INC·Filed 2005·Granted Oct 19, 2010·15 cites·25 claims
- 1689US6624194B1Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemiaMETABOLEX INC·Filed 2000·Granted Sep 23, 2003·38 cites·17 claims
- 1788US9161968B2Methods of neuroprotection involving macrophage colony stimulating factor receptor agonistsWYSS-CORAY ANTON·Filed 2012·Granted Oct 20, 2015·11 cites·9 claims
- 1887US6262118B1Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemiaMETS OLEX INC·Filed 1999·Granted Jul 17, 2001·61 cites·11 claims
- 1986US8030354B2Substituted biphenyl GPR40 modulatorsAMGEN INC·Filed 2008·Granted Oct 4, 2011·11 cites·96 claims
- 2085US7649110B2Compounds, pharmaceutical compositions and methods for use in treating metabolic disordersAMGEN INC·Filed 2005·Granted Jan 19, 2010·8 cites·37 claims
- 2184US2023226151A1Methods for Modulating Bile Acid Homeostasis and Treatment of Bile Acid Disorders and DiseasesNGM BIOPHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2283US5674900ATerpenoid-type quinones for treatment of diabetesSHAMAN PHARMACEUTICALS INC·Filed 1995·Granted Oct 7, 1997·38 cites·25 claims
- 2381US11141460B2Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disordersNGM BIOPHARMACEUTICALS INC·Filed 2019·Granted Oct 12, 2021·1 cites·10 claims
- 2480US7576131B2Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemiaMETABOLEX INC·Filed 2003·Granted Aug 18, 2009·12 cites·21 claims
- 2578US10688130B2Methods and compositions for treating aging-associated conditionsUNIV LELAND STANFORD JUNIOR·Filed 2014·Granted Jun 23, 2020·5 cites·8 claims
- 2676US5629319AHypoglycemic agent from cryptolepisSHAMAN PHARMACEUTICALS INC·Filed 1995·Granted May 13, 1997·18 cites·11 claims
- 2775US11103554B2Methods of using compositions comprising variants of FGF19 polypeptides for reducing bile acid synthesis in a subject having cirrhosisNGM BIOPHARMACEUTICALS INC·Filed 2019·Granted Aug 31, 2021·0 cites·55 claims
- 2872US2022072099A1Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disordersNGM BIOPHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2971US11564972B2Methods of using compositions comprising variants of FGF19 polypeptides for treating primary biliary cirrhosis in a subjectNGM BIOPHARMACEUTICALS INC·Filed 2018·Granted Jan 31, 2023·0 cites·18 claims
- 3069US10688154B2Methods of neuroprotection involving macrophage colony stimulating factor receptor agonistsUNIV LELAND STANFORD JUNIOR·Filed 2017·Granted Jun 23, 2020·0 cites·6 claims
- 3169US8354448B2Use of (−)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of type 2 diabetesMETABOLEX INC·Filed 2009·Granted Jan 15, 2013·0 cites·14 claims
- 3268US2019060403A1Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseasesNGM BIOPHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3367US7241743B2Sir2α-based therapeutic and prophylactic methodsUNIV COLUMBIA·Filed 2002·Granted Jul 10, 2007·2 cites·8 claims
- 3466US2019175692A1Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Treatment of Nonalcoholic Fatty Liver DiseaseNGM BIOPHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3566US2019175694A1Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Treatment of Liver FibrosisNGM BIOPHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3666US2020345812A1Methods of neuroprotection involving macrophage colony stimulating factor receptor agonistsUNIV LELAND STANFORD JUNIOR·Filed 2020·Application pending·0 cites
- 3766US2019175693A1Methods of Using Compositions Comprising Variants and Fusions of FGF19 Polypeptides for Treatment of CirrhosisNGM BIOPHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3862US2007270490A1Use of (-)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemiaMETABOLEX INC·Filed 2007·Application pending·0 cites
- 3960US2023107304A1Methods of treating cancer and tumor-related weight loss and cachexiaNGM BIOPHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4059US8329749B2Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of hyperuricemiaLUSKEY KENNETH L·Filed 2009·Granted Dec 11, 2012·0 cites·13 claims
- 4158US9796674B2Benzyl urea derivatives for activating TGF-beta signalingUNIV LELAND STANFORD JUNIOR·Filed 2014·Granted Oct 24, 2017·0 cites·5 claims
- 4258US2020390859A1Methods for treatment of bile acid-related disordersNGM BIOPHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4356US5747527AFuranoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetesSHAMAN PHARMACEUTICALS INC·Filed 1995·Granted May 5, 1998·7 cites·13 claims
- 4456US2005075396A1Use of (-)(3-trihalomethylphenoxy)(4-halophenyl) acetic acid derivatives for treatment of insulin resistance, Type 2 diabetes and hyperlipidemiaMETABOLEX INC·Filed 2003·Application pending·0 cites
- 4555US2008119434A1Sir2a-based therapeutic and prophylactic methodsTRUSTEES OF COLUBIA UNIVERSITY·Filed 2007·Application pending·0 cites
- 4655US2020352994A1Methods and compositions for treating aging-associated conditionsUNIV LELAND STANFORD JUNIOR·Filed 2020·Application pending·0 cites
- 4752US6779930B1Systems and methods for improving reproducibility of splice loss reduction in a pre-splice heat treatmentFITEL USA CORP·Filed 2003·Granted Aug 24, 2004·4 cites·15 claims
- 4850US8481597B2Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemiaLUSKEY KENNETH·Filed 2012·Granted Jul 9, 2013·0 cites·9 claims
- 4947US2003229025A1Intranasal administration of MC4-R agonistsCHIRON CORP·Filed 2003·Application pending·0 cites
- 5046US2007004743A1Intranasal administration of mc4-r agonistsXIAO LINDA L·Filed 2003·Application pending·0 cites
Showing the top 50 of 54 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jian Luo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →